X

Drug Profile

Pipamperone - ANeuroTech

Alternative Names: ANT-01; Pipamperone dihydrochloride - ANeuroTech

Latest Information Update: 05 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ANeuroTech
Class Antidepressants; Antipsychotics; Butyrophenones; Isonipecotic acids; Small molecules
Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Major depressive disorder

Most Recent Events

31 Jan 2024 Updated Safety data from a phase IIIa trial in Major depressive disorder released by ANeuroTech
14 Aug 2023 Chemical structure information added
05 Jun 2023 US FDA approves IND application for Pipamperone in Major depressive disorder

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com